iGii, the deep tech advanced materials company behind the proprietary Gii carbon nanotechnology, today announced the signing of a Master Services Agreement (“MSA”) and development programme with Merck, establishing a collaboration framework between the companies.
Gii is iGii’s proprietary carbon nanotechnology designed for deployment across multiple industrial environments through scalable manufacturing processes. The technology combines ultra-high carbon purity, exceptionally large electrochemically active surface area, anti-fouling behaviour and flexibility across multiple application environments.
“We are delighted to formalise this collaboration with Merck. What excites us most is the recognition that next-generation industrial and analytical systems will increasingly depend on breakthroughs at the material layer.
Merck’s scientific capability, global scale, and position across life science and advanced technology environments make them an exceptional organisation for iGii to work alongside as we continue expanding the deployment potential of Gii across future technologies and industrial environments.”
The collaboration represents a further step in iGii’s strategy of expanding adoption of Gii across multiple industries and application domains.
Further programme details remain confidential between the parties.
About iGii
iGii is a deep tech advanced materials company that has developed Gii, a proprietary carbon nanotechnology designed for scalable deployment across sensing, diagnostics, thermal systems, energy storage, and future intelligent hardware applications.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2025, Merck generated sales of € 21.1 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.